Want to see AU:ZLD full AI Analyst Report?
ZLD Stock Chart & Stats
AU$0.50
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.50
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.31 - AU$1.15
Previous CloseN/A
Volume19.14K
Average Volume (3M)0.00
Market Cap
AU$5.95M
Enterprise ValueAU$7.48
Total Cash (Recent Filing)AU$5.66K
Total Debt (Recent Filing)AU$2.14M
Price to Earnings (P/E)―
Beta1.72
Next Earnings
Mar 04, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.31
Shares Outstanding13,147,155
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-1.13
Price to Sales (P/S)7702.11
P/FCF Ratio-1.03
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Lean Cost Base (small Headcount)A very small employee base implies a lean operating structure that can reduce fixed overhead and slow cash burn. Over 2-6 months this provides flexibility to allocate capital to priority projects or scale via outsourcing and partnerships rather than costly internal expansion.
Multi-channel Monetization StrategyA dual pathway—consumer/product sales plus licensing and co-development—creates durable revenue optionality. Licensing can generate non-dilutive, recurring fees and milestone income, while commercialization upside remains if distribution partners scale sales, diversifying long-term cash sources.
Specialization In Cannabinoid Therapeutics & Consumer HealthA focused IP and product strategy in cannabinoid therapeutics and wellness (eg, sleep indications) aligns with structural industry interest in medical cannabis formulations. Specialized expertise and formulations are durable assets that can create niche competitive advantages if regulatory and commercial execution follow.
Bears Say
Severe Revenue Decline And Unprofitable OperationsAn extreme revenue collapse and persistent negative margins indicate the core business is not currently monetizing at scale. Over the medium term this erodes operating leverage, undermines reinvestment capacity, and requires meaningful new revenue engines or partner deals to restore sustainable profitability.
Negative Shareholders' Equity / Balance-sheet WeaknessNegative equity signals deep capital shortfall and weak solvency. Structurally, this constrains access to traditional debt, raises refinancing and covenant risk, and increases likelihood of dilutive or costly capital raises—limiting strategic flexibility until the balance sheet is repaired.
Negative Operating And Free Cash FlowsSustained negative operating and free cash flow means the business cannot self-fund R&D, regulatory work, or commercialization. Over a multi-month horizon this necessitates external financing, creating execution and timing risk for product launches, partnerships, and milestone realization.
Zelira Therapeutics News
ZLD FAQ
What was Zelira Therapeutics’s price range in the past 12 months?
Zelira Therapeutics lowest share price was AU$0.31 and its highest was AU$1.15 in the past 12 months.
What is Zelira Therapeutics’s market cap?
Zelira Therapeutics’s market cap is AU$5.95M.
When is Zelira Therapeutics’s upcoming earnings report date?
Zelira Therapeutics’s upcoming earnings report date is Mar 04, 2027 which is in 180 days.
How were Zelira Therapeutics’s earnings last quarter?
Zelira Therapeutics released its earnings results on Aug 29, 2025. The company reported -AU$0.104 earnings per share for the quarter.
Is Zelira Therapeutics overvalued?
According to Wall Street analysts Zelira Therapeutics’s price is currently Overvalued.
Does Zelira Therapeutics pay dividends?
Zelira Therapeutics does not currently pay dividends.
What is Zelira Therapeutics’s EPS estimate?
Zelira Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Zelira Therapeutics have?
Zelira Therapeutics has 13,147,155 shares outstanding.
What happened to Zelira Therapeutics’s price movement after its last earnings report?
Zelira Therapeutics reported an EPS of -AU$0.104 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Zelira Therapeutics?
Currently, no hedge funds are holding shares in AU:ZLD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Zelira Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Learn more about TipRanks Smart Score
Company Description
Zelira Therapeutics
Zelira Therapeutics Limited (ZLD.AX) is an Australian biopharmaceutical firm dedicated to the research, development, and commercialization of cannabinoid-derived medicines for a variety of medical conditions. Its product portfolio includes HOPE™ brand formulations, which are available in Pennsylvania and Louisiana, as well as Zenivol™, a cannabinoid-based medication designed to treat chronic insomnia. In addition to its prescription offerings, the company provides several over-the-counter (OTC) products. These include SprinJene™ for oral hygiene and RAF FIVE™ for dermatological applications. Zelira also markets ITURA™, an advanced topical relief cream formulated to target multiple symptoms such as numbness, tingling, muscle cramps, insensitivity, and pain associated with Peripheral Artery Disease and diabetes. Zelira maintains key strategic partnerships with academic and medical institutions, including Curtin University, the Telethon Kids Institute, the University of Western Australia, St. Vincent's Hospital, and the Children's Hospital of Philadelphia. Originally incorporated in 2003 as Zelda Therapeutics Limited, the company rebranded to Zelira Therapeutics Limited in December 2019. Its corporate headquarters are located in Perth, Australia.
Technical Analysis
Actinogen Medical
―
Tryptamine Therapeutics
―
Paradigm Biopharmaceuticals
―
Island Pharmaceuticals Ltd
―
Botanix Pharmaceuticals Limited
―